{
    "nctId": "NCT04921137",
    "briefTitle": "Evaluating Harms and Benefits of Endocrine Therapy in Patients \u226570 Years of Age With Lower Risk Breast Cancer",
    "officialTitle": "A Randomised, Multicentre Trial Evaluating Harms and Benefits of Endocrine Therapy in Patients \u226570 Years of Age With Lower Risk Breast Cancer (REaCT-70)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 109,
    "primaryOutcomeMeasure": "Accrual of 100 participants across 8 centres within 2 years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* New invasive estrogen and/or progesterone receptor-positive (ER+ and/or PR+), HER2-negative (HER2-) invasive breast carcinoma diagnosis as per ASCO-CAP guidelines\n* The primary tumour characteristics are either: Grade 1 and \u22645 cm on microscope exam, OR Grade 2 and \u22643 cm on microscope exam, OR Grade 3 and \u22641 cm on microscope exam\n* Treated with standard loco-regional therapy: breast conserving surgery followed by adjuvant radiotherapy OR total mastectomy\n* Axillary lymph node-negative (N0)\n* Able to provide oral consent and complete questionnaires in French or English as per study protocol\n\nExclusion Criteria:\n\n* Metastatic cancer",
    "sex": "ALL",
    "minimumAge": "70 Years",
    "stdAges": "OLDER_ADULT"
}